A Study of MGC026 in Participants With Advanced Solid Tumors

Key facts

Sponsor

MacroGenics

Principal Investigator

Denise Casey, MD

MacroGenics

Intervention

MGC026 Dose Escalation(biological)

Enrollment

250 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2028

Study locations (12)

• The Angeles Clinic and Research Institute, Los Angeles, California, United States
• START Midwest, Grand Rapids, Michigan, United States
• START-New York Long Island, Lake Success, New York, United States
• Providence Cancer Institute, Portland, Oregon, United States
• The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
• University of Texas Health Science Center at Houston, Houston, Texas, United States
• START Mountain Region, West Valley City, Utah, United States
• ICON Cancer Centre Wesley, Auchenflower, Queensland, Australia
• ICON Cancer Centre Kurralta Park, Kurralta Park, South Australia, Australia
• Austin Health- Olivia Newton John Cancer Center, Heidelberg, Victoria, Australia
• Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
• The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of head and neck

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07333274
  Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
  Shandong Cancer Hospital and Institute
• RECRUITINGPHASE3NCT07026474
  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
  Universität des Saarlandes
• RECRUITINGPHASE1NCT07182149
  A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
  Normunity AccelCo, Inc.
• RECRUITINGNANCT07203911
  Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
  Tobias Todsen
• RECRUITINGNANCT07180901
  Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
  Centre hospitalier de l'Université de Montréal (CHUM)
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415
  Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
  China Medical University Hospital
• RECRUITINGPHASE2NCT07088211
  Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• RECRUITINGPHASE2NCT07040956
  A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
  West China Hospital

See all trials for Squamous cell carcinoma of head and neck →